Belkengren, Richard; Sapala, Shirley
March 2000
Pediatric Nursing;Mar/Apr2000, Vol. 26 Issue 2, p182
Academic Journal
Presents the case of a 14-year-old female with Type I diabetes. Social and family history; Factors that contributed to the occurrence of hypoglycemia; Treatment for the disease.


Related Articles

  • Limitations of HbA[sub1c] in diabetes control.  // Pulse;3/24/2003, Vol. 63 Issue 12, p88 

    Discusses the limitations of the HbA[sub 1c] in aiding the treatment of type 2 diabetes. Method of monitoring the effectiveness of therapy in diabetes; Clinical advantages of measuring fructosamine level.

  • New diabetes treatments may be on horizon.  // Diabetes in the News;Nov/Dec94, Vol. 13 Issue 6, p3 

    Reports on studies regarding new therapies for type II diabetes. Food and Drug Administration's (FDA) pending approval of an oral agent called metformin; Studies on thiazoles and vanadates; Mechanism of action of tolrestat; Use of combination drug approach in diabetes-related impotence; Use of...

  • Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes.  // Formulary;Feb2010, Vol. 45 Issue 2, p34 

    An abstract of the article "Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes," by Ashley Krause and Jennifer Kirwin is presented.

  • Managing Obesity as First-Line Therapy for Diabetes Mellitus. Kelley, David E. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p38 

    Focuses on the management of obesity for the treatment of type 2 diabetes mellitus in the United States. Improvement of weight loss in obese patients; Impact of weight loss on the clinical efficacy of concominant pharmacologic therapy; Reduction of skeletal muscles insulin resistance.

  • Newer, controlled-release glipizide is superior to its conventional form.  // Modern Medicine;Mar95, Vol. 63 Issue 3, p53 

    Presents an abstract of the article `Comparative Efficacy of a Once-daily Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Patients With NIDDM,' by M. Berelowitz, C. Fischette et al dated December 1994.

  • New hypoglycemic should help physicians `do a better job'.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p28 

    Reports on the approval of the drug glimepiride for the treatment of noninsulin-dependent diabetes by 1995. Oral hypoglycemics as a tool for caring for noninsulin-dependent diabetes; Recommended dosage for glimepiride; Study presented at the Ameri can Diabetes Association Conference held in...

  • Diabetes study compares intensive therapy with diet alone.  // Modern Medicine;Sep96, Vol. 64 Issue 9, p13 

    Reports on the result of the comparative study concerning the ability of intensive therapy to improve glucose control and simple diet in patients who have newly diagnosed non-insulin dependent diabetes. Result of the trial study; Comparison of the diet with three drug regimens, sulfonylureas,...

  • Intensive insulin therapy not yet recommended for NIDDM.  // Geriatrics;Jun95, Vol. 50 Issue 6, p57 

    Presents an abstract of the article `Do Results from the Diabetes Control and Complications Trial Apply in NIDDM?' by D.M. Nathan from Diabetes Care 1995.

  • Discuss risks and benefits before intensifying type 2 diabetes treatment.  // Geriatrics;Jan98, Vol. 53 Issue 1, p26 

    Focuses on treatment for type II diabetes, highlighting the need for the discussion of risks and benefits involved in such treatment. Comments from Sandeep Vijan, M.D., M.S., a lecturer of internal medicine at the University of Michigan School of Medicine; Details on a study conducted by Vijan...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics